Bank of Communications' First-Half Net Profit Climbed 4.9% on Trading Gains
By Kosaku Narioka
Bank of Communications said Friday that its first-half net profit rose 4.9% from a year earlier, thanks partly to gains from its trading activities despite a drop in net interest income.
The Chinese bank said net profit increased to 42.52 billion yuan ($5.84 billion) for the six months ended June 30 from CNY40.535 billion a year earlier. That missed the estimate of CNY46.69 billion from a poll of analysts by Visible Alpha.
First-half net interest income dropped 3.1% from a year earlier to CNY82.39 billion, as interest rates in the country have fallen in recent quarters. Net fee and commission income also declined 0.8% to CNY24.58 billion.
Meanwhile, net gains arising from trading activities surged 77% to CNY17.64 billion, thanks partly to the growth of subsidiaries' equity investments and gain on changes in fair value.
Credit impairment losses declined 1.3% from a year earlier to CNY36.35 billion. The bank's nonperforming loan ratio was at 1.35%, steady from the end of 2022.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
August 25, 2023 05:35 ET (09:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks